Patents

342 articles available

The UK approach to plausibility and, in particular, the decisions in relation to apixaban and dapagliflozin , have ensured that the UK continues to be a fertile hunting ground for generic companies…

Forxiga (dapagliflozin), developed by BMS/AstraZeneca, is now making room for generics to squeeze in. In Russia, this process has been dramatically accelerated: the latest court case has ruled that…

COMVIK and G 1/19 “technical character” as a shared filter, and what happens when inventive step is not assessed using the EPO’s problem–solution approach.Europe has long grappled with the exclusions…

The Munich Local Division has now given the UPC’s first ruling applying the “lay open books” procedure under Rule 141 of the UPC Rules of Procedure (r. 141). For parties litigating in the UPC, this…

In two of its recent decisions (apixaban and sacubitril-valsartan), the Czech Industrial Property Office (CZ IPO) has considered the application of decision G-2/21 (plausibility) of the Enlarged…

The European Innovation Act, proposed on 9 September 2026, has understandably attracted attention chiefly as a procurement measure, although Chapter 3 creates a separate architecture for IP-backed…

The UK Supreme Court has considered the fundamental principles of (F)RAND, this time in the context of a jurisdiction challenge in Tesla v InterDigital and Avanci. In what could prove to be a…

On March 3, 2026, the Osaka District Court dismissed a patent infringement lawsuit seeking an injunction against a generic drug, addressing an unprecedented question regarding the scope of extended…

Abstract:FRAND licensing asks implementers to pay today for a benchmark that courts may only define tomorrow – often in disputes to which they were not a party. When later decisions show that agreed…